Health

  • January 05, 2026

    1st Circ. Upholds Block On Trump Admin NIH Funding Cuts

    The First Circuit on Monday affirmed a Massachusetts federal judge's order permanently blocking the Trump administration from gutting National Institutes of Health funding for biomedical research, agreeing that the government didn't have the authority to cap indirect costs for research grants.

  • January 05, 2026

    Exelon, Nursing Home Operator Sued Over Fatal Explosion

    PECO Energy Co., its parent company Exelon Corp. and multiple healthcare entities were hit with a lawsuit on Monday alleging they knew about gas leaks that led to a fatal nursing home explosion in Bucks County, Pennsylvania, that killed two and injured over a dozen more, but failed to act in time.

  • January 05, 2026

    Fla. AG Says Pot Legalization Proposal 'Misleads Voters'

    Florida Attorney General James Uthmeier is opposing a new effort to legalize recreational marijuana through a ballot initiative, telling the state's high court that the proposal is invalid because it "misleads voters." 

  • January 05, 2026

    Fed. Circ. Examines Timing Of $452M Trade Secrets Suit

    A Federal Circuit panel delved into the statute of limitations for trade secrets cases Monday, pressing an attorney for a South Korean company seeking to reverse a verdict that prompted a $452 million jury award to explain why the clock should start when a plaintiff suspects misappropriation rather than when it is actually discovered.

  • January 05, 2026

    Express Scripts Wants FTC Atty Views On Insulin Prices

    Express Scripts is seeking to force an attorney from the Federal Trade Commission to sit for a deposition in the agency's case accusing pharmacy benefit managers of inflating insulin prices, saying the commission's own attorneys acknowledge that manufacturers cause higher prices.

  • January 05, 2026

    NC Anesthesiologists Dismiss Pay Cut Dispute With Board

    A group of North Carolina anesthesiologists voluntarily dismissed their lawsuit accusing business partners of unlawfully slashing monthly compensation in retaliation for questioning a proposed fee-sharing arrangement, according to a notice filed in North Carolina Business Court.

  • January 05, 2026

    Cancer Biotech Co. Eyes $182M IPO

    A company developing new drugs for treating cancer disclosed Monday it is looking to raise roughly $182 million in an initial public offering guided by Paul Hastings LLP and Davis Polk & Wardwell LLP, teeing it up for the first major IPO of 2026.

  • January 05, 2026

    Aetna Drug Price-Fixing Suit Against Pharma Cos. Paused

    A judge has paused Aetna Inc.'s Connecticut Superior Court lawsuit accusing nearly two dozen pharmaceutical companies of fixing the prices of generic drugs, refusing drugmakers' bids to dismiss the case but agreeing to put it on hold pending the outcomes of similar cases in other jurisdictions.

  • January 05, 2026

    Health Officials Roll Back Child Vaccine Recommendations

    Amid public outcry, federal health officials on Monday revised vaccine recommendations for American children, cutting the number from 18 to 11 and bringing the United States in line with other developed countries such as Denmark. 

  • January 05, 2026

    Calif. Tribe Sues IHS Over Opioid Center Compact Denial

    A California tribe is asking a federal court to order the Indian Health Service to approve a proposed agreement for an opioid treatment center, arguing that the funding is desperately needed after multiple tragedies due to drug addiction in and outside its reservation.

  • January 05, 2026

    Simpson Thacher Opens San Francisco Office

    Simpson Thacher & Bartlett LLP is expanding its California presence, announcing Monday it has opened an office in San Francisco.

  • January 05, 2026

    Ind. Sues Eli Lilly Over 'Grossly Inflated' Insulin Prices

    Indiana's attorney general on Monday announced a state court suit against Eli Lilly alleging it schemed to artificially inflate the price of insulin, saying the litigation follows two years of ultimately unsuccessful attempts to resolve the matter without litigation against the drug manufacturer.

  • January 05, 2026

    DOL Names Acting Benefits Official For EBSA Operations

    The U.S. Department of Labor has appointed a senior official to oversee program operations for the agency's employee benefits subdivision, according to a Monday update on the agency's online organization chart.

  • January 05, 2026

    Trump Backs Biden's Medicare Drug Price Law At High Court

    The Trump administration is defending the Biden-era Medicare Drug Price Negotiation program to the U.S. Supreme Court, asking the justices to deny AstraZeneca's petition challenging the program as unconstitutional.

  • January 05, 2026

    Federal Workers Fight Gender-Affirming Coverage Rollback

    A group of federal employees has filed a discrimination complaint with the U.S. Office of Personnel Management, saying the decision to end coverage for certain gender-affirming medical procedures under the workers' health insurance plans amounted to unlawful sex bias.

  • January 05, 2026

    Thesis Supplements Illegally Sold As ADHD Drugs, Suit Says

    A Louisiana woman is suing the owner of Thesis Nootropics in New York federal court, alleging that the company's line of supplements is illegally marketed as an alternative to Adderall and other medications despite lacking federal approval.

  • January 05, 2026

    Paul Hastings Adds Hogan Lovells Duo To Life Sciences Team

    Two longtime Hogan Lovells partners, including the head of its pharmaceutical and biotechnology regulatory practice, have joined Paul Hastings LLP in Washington, D.C., the firm announced Monday.

  • January 02, 2026

    NC Hospital, Nurses Score Initial OK For $75K Meal Break Deal

    A North Carolina hospital will pay $75,000 to end an overtime lawsuit alleging it automatically deducted meal breaks from nurses' pay, according to a federal judge's order initially approving the settlement.

  • January 02, 2026

    IRS Floats Updates To Fee Paid By Brand Drugmakers

    The Internal Revenue Service floated updates to regulations governing how branded prescription drug manufacturers or importers should calculate an annual fee established by the Affordable Care Act, a move the agency said aims to incorporate changes in drug discount programs and clarify tax reporting.

  • January 02, 2026

    Bankruptcy And Restructuring Trends To Watch In 2026

    Bankruptcy practitioners expect restructuring activity to remain elevated in the year ahead as more debt comes due and businesses continue to grapple with economic uncertainty. Major court rulings on bankruptcy plans, innovations in out-of-court debt deals and shifts in what is permitted under Chapter 11 will also have important effects in 2026, experts told Law360.

  • January 02, 2026

    Drug Pricing Battles To Watch In 2026

    With drugmakers already pushing back on drug affordability programs and policies, Law360 looks at the year ahead for litigation focused on state and federal drug pricing programs.

  • January 02, 2026

    Approach The Bench: What Judges Had To Say In 2025

    Jurists discussed their strategies for decision-making, the difficulties of case management, and their predictions for the future of litigation in a dozen interviews with Law360 this year.

  • January 02, 2026

    5 Cases In Georgia To Keep An Eye On In 2026

    Attorneys in Georgia will be watching several legal battles involving hot-button issues in the new year, including a suit over gender-affirming healthcare in state prisons, multidistrict litigation seeking to hold Meta and others liable for alleged social media addiction, and a bid by the U.S. Justice Department to obtain 2020 election records. Here is a look at five cases to follow in 2026.

  • January 02, 2026

    Product Liability Cases To Watch In 2026

    Trials in the massive litigation against social media giants like Facebook are set to start in the New Year, as litigants battle over whether the companies should be held responsible for allegedly designing their platforms to addict youth, causing a bevy of mental health harms, and cases against popular weight loss drugs like Ozempic continue to mount. Here's what else product liability attorneys will be watching in 2026.

  • January 02, 2026

    5 Policy Areas Benefits Attys Should Keep Tabs On In 2026

    The new year promises policy shifts that could change the legal landscape for health and retirement benefits, including action to follow through on an executive order encouraging alternative assets in 401(k) plans, and a potential replacement for a Biden-era rule covering how retirement plan managers can factor environmental and social issues into their investment strategy. Here are five policy areas benefits attorneys will be watching in 2026.

Expert Analysis

  • SDNY OpenAI Order Clarifies Preservation Standards For AI

    Author Photo

    The Southern District of New York’s recent order in the OpenAI copyright infringement litigation, denying discovery of The New York Times' artificial intelligence technology use, clarifies that traditional preservation benchmarks apply to AI content, relieving organizations from using a “keep everything” approach, says Philip Favro at Favro Law.

  • 4 Strategies To Ensure Courts Calculate Restitution Correctly

    Author Photo

    Recent reversals of restitution orders across the federal appeals courts indicate that some lower courts are misapplying fundamental restitution principles, so defense attorneys should consider a few ways to vigilantly press these issues with the sentencing judge, says Wesley Gorman at Comber Miller.

  • Assessing The Future Of The HIPAA Reproductive Health Rule

    Author Photo

    In light of a Texas federal court's recent decision to strike down a U.S. Department of Health and Human Services rule aimed to protect the privacy of patients seeking abortions and gender-affirming care, entities are at least temporarily relieved from compliance obligations, but tensions are likely to continue for the foreseeable future, says Liz Heddleston at Woods Rogers.

  • Opinion

    Expert Reports Can't Replace Facts In Securities Fraud Cases

    Author Photo

    The Ninth Circuit's 2023 decision in Nvidia v. Ohman Fonder — and the U.S. Supreme Court's punt on the case in 2024 — could invite the meritless securities litigation the Private Securities Litigation Reform Act was designed to prevent by substituting expert opinions for facts to substantiate complaint assertions, say attorneys at A&O Shearman.

  • Opinion

    High Court, Not A Single Justice, Should Decide On Recusal

    Author Photo

    As public trust in the U.S. Supreme Court continues to decline, the court should adopt a collegial framework in which all justices decide questions of recusal together — a reform that respects both judicial independence and due process for litigants, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Series

    Traveling Solo Makes Me A Better Lawyer

    Author Photo

    Traveling by myself has taught me to assess risk, understand tone and stay calm in high-pressure situations, which are not only useful life skills, but the foundation of how I support my clients, says Lacey Gutierrez at Group Five Legal.

  • Opinion

    DOJ's Tracing Rule For Pandemic Loan Fraud Is Untenable

    Author Photo

    In conducting investigations related to COVID-19 relief fraud, the government's assertion that loan proceeds are nonfungible and had to have been segregated from other funds is unsupported by underlying legislation, precedent or the language establishing similar federal relief programs, say Sharon McCarthy, Jay Nanavati and Lasya Ravulapati at Kostelanetz.

  • New Health AI Guidance Features A Provider-Centric Approach

    Author Photo

    New guidance from the Joint Commission and Coalition for Health AI regarding the responsible use of artificial intelligence in healthcare deviates from preexisting guidance by recommending a comprehensive framework for using AI tools, focusing on healthcare provider organizations rather than on AI developers, say attorneys at Ropes & Gray.

  • Series

    Law School's Missed Lessons: Client Service

    Author Photo

    Law school teaches you how to interpret the law, but it doesn't teach you some of the key ways to keeping clients satisfied, lessons that I've learned in the most unexpected of places: a book on how to be a butler, says Gregory Ramos at Armstrong Teasdale.

  • How Occasional Activists Have Reshaped Proxy Fights

    Author Photo

    The sophistication and breadth of first-time activist engagement continue to shape corporate governance and strategic outcomes, as evidenced across corporate annual meetings this summer, meaning advisers should anticipate continued innovation in tactics, increased regulatory complexity, and a persistent focus on board accountability, say attorneys at MoFo.

  • Bid Protest Spotlight: Documentation, Overrides, Eligibility

    Author Photo

    Recent decisions by the U.S. Court of Federal Claims and the U.S. Government Accountability Office illustrate the importance of contemporaneous documentation in proposal evaluations, the standards for an agency’s override of a Competition in Contracting Act stay, and the regulatory requirements for small business joint ventures, says Cody Fisher at MoFo.

  • Shutdown Imperils Telehealth Access For Medicare Patients

    Author Photo

    The federal government shutdown that commenced on Oct. 1 coincided with the expiration of certain telehealth flexibilities that had preserved expansive access to telehealth services for Medicare beneficiaries following COVID-19, creating significant legal and financial uncertainty for healthcare providers and patients, say attorneys at Robinson & Cole.

  • Mass. Ruling May Pave New Avenue To Target Subpoenas

    Author Photo

    A Massachusetts federal court’s recent decision to quash a subpoena seeking information on gender-affirming care at Boston Children’s Hospital is a significant departure from courts' deferential approach to subpoena enforcement, and may open a new pathway for practitioners challenging investigative tools in the future, say attorneys at Gibson Dunn.

  • What To Expect After FDA Warnings To GLP-1 Compounders

    Author Photo

    The U.S. Food and Drug Administration's recent warning letters to companies advertising compounded versions of GLP-1 medications raise questions not just about the enforcement outlook for marketing such products, but also about the future of drug compounding as a whole, say attorneys at Spencer Fane.

  • Why Justices Seem Inclined To Curtail Del. Affidavit Statute

    Author Photo

    After recent oral argument before the U.S. Supreme Court in Berk v. Choy — asking whether Delaware's affidavit-of-merit statute applies in federal diversity actions, or whether the Federal Rules of Civil Procedure displace the state requirement — it appears the court is poised to simplify the standard approach, says Eric Weitz of The Weitz Law Firm.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.